UDCA powder is the most researched and proved to be effective drug in recent years, with the advantages of small dose and low toxicity. Ursodeoxycholic acid can not only promote the dissolution of cholesterol stones, but also replace the toxic bile acids in human body and inhibit them from damaging the bile cells, thus realizing the purpose of treating intrahepatic cholestasis syndrome.
In recent years, the incidence of intrahepatic cholestasis during pregnancy has been increasing due to the increasing number of elderly mothers. Studies have shown that cholestasis during pregnancy leads to a decline in maternal liver function, making it difficult to continue normal physiological processes such as catabolism and detoxification. Elevated concentrations of bile acids are carried in the bloodstream through the umbilical cord to the fetus. The high concentration of bile acids mediates increased vasoconstriction of the placental villous surface, increased vascular resistance, and a sudden decrease in placental oxygenated blood flow. Eventually, fetal blood perfusion is drastically reduced, inducing acute hypoxia.
In severe cases, this can lead to perinatal death. A histomorphologic study of the placentas of patients with cholestasis in pregnancy revealed that abnormal proliferation of placental trophoblast cells and increased chorionic syncytiotrophoblast nodules were observed in pathological section experiments. The syncytiotrophoblast nodules are a natural aging and degeneration phenomenon of the trophoblast cells of the villi. The placentas of patients with cholestasis in pregnancy had significantly more syncytiotrophoblast nodules than the placentas of normal full-term pregnancies. The results suggest that increased syncytiotrophoblast apoptosis plays an important role in the development of pathological changes in the placenta.
Excessive TBA in the maternal serum after intrahepatic cholestasis can further stimulate the placental villous vasculature. This leads to inadequate perfusion of placental blood flow, which interferes with fetal oxygen supply after entering the fetal circulation via the placenta. It also negatively affects the vascular function and immune function of both mother and child. Therefore, it is considered important to actively explore efficient and safe treatment options for mother and child outcomes in intrahepatic cholestasis syndrome during pregnancy.
Patients with intrahepatic cholestasis in pregnancy mainly present with itching without skin lesions, which is mild during the day and intense at night. The patient's daily life is disturbed. Elevated serum bile acids are the direct cause of the cholestatic symptoms. Therefore, a significant abnormality in a sensitive indicator of hepatic impairment is often indicative of cholestasis. UDCA powder belongs to the group of cholesteric acid compounds and is one of the active ingredients isolated from bear bile. It does not require biotransformation and has a high cytoprotective effect and membrane stability. It can be combined with glycine or taurine in the liver. It is excreted from the bile into the small intestine. The specific mechanism of action of ursodeoxycholic acid in the treatment of this disease. Blocks the activation of blastic cells by toxic bile acids. Competitively antagonizes ileal absorption of endogenous toxic bile acids, reduces oxidative damage to hepatocytes, and protects hepatocyte function. With the advantages of non-toxicity and hydrophilicity, it can gradually restore the secretion of endogenous bile acids in maternity. Thus, it can reduce the high concentration of bile acid in bile and blood, relieve cholestasis while inhibiting intestinal absorption of endogenous bile acid. Ultimately, it is conducive to promoting the recovery of the patient's liver function.
Intrahepatic cholestasis not only affects maternal health, but also threatens the normal growth and development of the fetus. High bile acid level will interfere with fetal steroid metabolism, and a series of pathological changes will occur in the fetus. Ursodeoxycholic acid has a role in regulating the dynamic balance of the hepatic and intestinal circulation. Ursodeoxycholic acid mediates the change of cholesterol in bile from a supersaturated state to a non-saturated state. Inhibition of intestinal absorption of cholesterol is accompanied by inhibition of biliary secretion of cholesterol. Ursodeoxycholic acid is mainly metabolized by intestinal flora to water-insoluble lithocholic acid and excreted in the feces, avoiding accumulation of the drug. Ursodeoxycholic acid improves clinical symptoms in pregnant women with intrahepatic cholestasis. It is also effective in relieving placental chorionic cholestasis and improving the environment for fetal development.
Ursodeoxycholic acid (UDCA) treatment has been demonstrated to be successful in treating patients with intrahepatic cholestasis of pregnancy (ICP), otherwise called intrahepatic cholestasis disorder (ICS). This is the way UDCA treatment can influence patients with ICP:
• Bile Corrosive Levels:
ICP is described by an aggregation of bile acids in the liver and circulation system. These raised degrees of bile acids might possibly hurt both the mother and baby. UDCA treatment assists with diminishing the convergence of bile acids, subsequently reducing the side effects and potential confusions related with ICP.
• Side effect Alleviation:
ICP frequently gives serious tingling, especially on the centers of the hands and bottoms of the feet. UDCA treatment can assist with lightening this upsetting side effect and work on the personal satisfaction for pregnant ladies with ICP.
• Liver Capability:
UDCA has hepatoprotective properties, and that implies it can help safeguard and work on liver capability. In ICP, liver capability might be compromised because of the gathering of bile acids. UDCA powder treatment can assist with lessening liver chemical levels and further develop liver capability tests in patients with ICP.
• Fetal Results:
ICP is related with an expanded gamble of unfriendly results for the baby, including preterm birth, fetal trouble, and stillbirth. UDCA treatment has been displayed to decrease these dangers, possibly working on fetal results in ladies with ICP.
UDCA powder may improve the outcome of pregnancies complicated by intrahepatic cholestasis in pregnancy. In conclusion, the recovery of liver function in patients with intrahepatic cholestasis in pregnancy is more favorable after the application of ursodeoxycholic acid. Clinical symptoms were effectively relieved and pregnancy outcome was improved.
Guanjie is a bulk UDCA supplier. We have also passed Halala, Kosher, ISO and other certificates. We support customized products. To get a free sample, please contact our experts at info@gybiotech.com.
